Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials

  1. Azita H. Talasaz
  2. Parham Sadeghipour
  3. Hessam Kakavand
  4. Maryam Aghakouchakzadeh
  5. Elaheh Kordzadeh-Kermani
  6. Benjamin W. Van Tassell
  7. Azin Gheymati
  8. Hamid Ariannejad
  9. Seyed Hossein Hosseini
  10. Sepehr Jamalkhani
  11. Michelle Sholzberg
  12. Manuel Monreal
  13. David Jimenez
  14. Gregory Piazza
  15. Sahil A. Parikh
  16. Ajay Kirtane
  17. John W. Eikelboom
  18. Jean M. Connors
  19. Beverley J. Hunt
  20. Stavros V. Konstantinides
  21. Mary Cushman
  22. Jeffrey I. Weitz
  23. Gregg W. Stone
  24. Harlan M. Krumholz
  25. Gregory Y.H. Lip
  26. Samuel Z. Goldhaber
  27. Behnood Bikdeli
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and critically-ill patients with COVID-19. This manuscript provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.

Related articles

Related articles are currently not available for this article.